MIRA INFORM REPORT
|
Report Date : |
23.11.2011 |
IDENTIFICATION DETAILS
|
Correct Name : |
DORI-DARMON AK |
|
|
|
|
Formerly Known As : |
Dori-Darmon GAA |
|
|
|
|
Registered Office : |
Chorsu Square 21 (frmlyAkhunbabaeva), Shaykhantakhursky, Tashkent
100021 |
|
|
|
|
Country : |
Uzbekistan |
|
|
|
|
Financials (as on) : |
01.10.2010 |
|
|
|
|
Date of Incorporation : |
11.04.1994 |
|
|
|
|
Com. Reg. No.: |
27, as of 1 June 1994, Ministry of Justice |
|
|
|
|
Legal Form : |
Joint Stock Company |
|
|
|
|
Line of Business : |
Importers, wholesalers
and retailers of
pharmaceuticals |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
SUM 2,500,000,000 |
|
Status : |
Satisfactory |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30th, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
Uzbekistan |
b2 |
b2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name
Dori-Darmon AK (Correct)
J
S C DoriDarmon(Requested)
company ADDRESS
Street
: Chorsu
Square 21 (frmlyAkhunbabaeva)
Area :
Shaykhantakhursky District
Town : Tashkent
100021
Country : Uzbekistan
Telephone : (998 71) 144 0097 /
120 3836 / 120 3803 (International Relations Department)/ 120 3831
(Accounts) / 120 4848 / Mobile (998
93) 181 1001
Fax
: (998 71) 144 8368 /
120 3835
E-Mail : uruzieva@doridarmon.uz / s.s.nasretdinov@doridarmon.uz / office@doridarmon.uz
/
Website :
www.doridarmon.uz
English Translation :
Dori-Darmon Joint Stock Company
Formerly Known As :
Dori-Darmon GAA
Also Known As :
Dori-DarmonAktsionernayaKompaniya
SENIOR COMPANY PERSONNEL
Name Position
1. UmidaSaidovnaSalikhbayeva Chairman
2.IlyozDzhabarovichRazakov Deputy
Chairman / Finance
3.MakhsudSalikhovichFaiziyev Deputy
Chairman
4.UmidaRuzieva Head
of International Relations Department
5.SaidvaliSaidnabiyevichNasretdinov Chief Accountant
6. MuatarRakhimzhanovaDeputy
Chief Accountant
7.
HurshidaEshbeeva International Relations Manager
Total Employees : 412
(subject)
3,500 (group)
PAYMENTS
No
complaints have been heard regarding payments from local suppliers or banks.
Subject is the leading pharmaceutical enterprise in Uzbekistan market
supplying people and therapeutic institutions of the Republic with
pharmaceutical production for more than 85 years. Subject has its own
regional subdivisions including 9 joint-stock corporations and 10
subsidiaries with infrastructure of 18 warehouses, 15 analytical
control laboratories, 574 pharmacy institutions.
We consider it is acceptable to deal with subject for LARGE amounts,
although it is normal accepted practice for international suppliers
to deal on secured terms with Uzbekistani importers.
Opinion on maximum credit : SUM 2,500,000,000
Trade risk assessment : Normal
PRINCIPAL BANKERS
NAME :
NATIONAL BANK FOR FOREIGN ECONOMIC ACTIVITY OF UZBEKISTAN
Branch :
MirzoUlugbeksky Branch
Street :
ulitsaPushkina 66
Town :
Tashkent
Telephone : (998 71) 137 2273 /
137 0121
Fax
: (998 71) 137 0121
Acc. No.: 20208000600109326001
Acc. NO.: 20208000900109326004
MFO :00895
The company also has an account with:
IpakYuli Bank
ulitsaFarkhadskaya 12A
Tashkent 100135
Telephone: (998 71) 120 0009 / 120 3899 / 116 1991
Fax : (998 71) 120 3886
Acc. No. : 2980100300109326001
MFO :00444
FINANCIAL INFORMATION
Balance Sheets as at 1 October 2010 showed :
31/12/2009 30/09/2010
(In thousand SUM)
ASSETS
Long-term assets:
Fixed Assets
Initial (replacement) value 4,540,230 6,606,896
Amortization amount 1,224,881 1,495,508
Residual(book) value 3,315,349 5,111,388
Intangibles
Initial cost - 181,975
Amortization - 19,931
Residual(book) value - 162,044
Long-terminvestments, total 2,807,380 4,972,323
Securities - -
Investments in subsidiaries and
business entities 1,235,857 3,400,800
Investment in dependent companies 1,571,523 1,571,523
Investments in venture with a
foreign-capital - -
Other long-term investments - -
Equipment to be installed 212,782 315,492
Capital investments 466,180 4,279,086
Long-term receivables - -
Long-term deferred expenses - -
Total Section I 6,801,691 14,840,333
Currentassets
Total inventories 32,333,256 20,588,088
Productive reserves 160,963 183,981
Work in progress - -
Finished goods - -
Goods
32,172,293
20,404,107
Deferred expenses 429,709 1,150,660
Total debtors 9,264,378 9,311,326
Overdue debts
Receivables from buyers 139,808 168,474
Debts of separate divisions - -
Debts of subsidiaries and affiliates 8,858,629 8,213,555
Advances tostaff - -
Advancesto suppliersandcontractors 13,271 273,562
Advancepaymentsof taxes andduties
to state budget 1,553 -
Advancepaymentstogovernment
trust fundsandinsurance - -
Shareholders debt to capital
Contributions - -
Arrears of staff on other transactions 90 3,223
Otherreceivables 251,027 654,512
Cash, including 8,846,390 15,960,888
Cash in hand 12,426 30,523
Cashin the bankaccount 1,342,171 10,229,105
Funds in foreign-currency 58,250 78,660
Othercash and cashequivalents 7,433,543 5,622,600
Short-term investments - 150,000
Othercurrent assets - -
Total Section II 50,873,733 47,160,962
Totalasset balance 57,675,424 62,001,295
EQUITY
Sharecapital 8,028,800 16,057,600
Added capital
5,851 5,851
Reserve capital 1,198,556 1,829,943
Treasury shares - -
Retainedearnings (loss) 12,190,492 9,537,718
Directed receipts 3,225,513 3,459,566
Provisions for liabilities and
payments - -
TOTALEQUITY 24,649,212 30,890,678
LIABILITIES
Long-termliabilitiestotal 2,030,831 -
including, long-termpayables 30,831 -
Long-term debt to suppliers and
contractors - -
Long-term arrears separate divisions - -
Long-term debts of subsidiaries
and affiliates - -
Long-term deferred expenses - -
Long-term deferred tax liabilities
and obligatory payments - -
Other long-term deferred liabilities - -
Advances received from customers
and clients - -
Long-termbankloans - -
Long-term loans 2,000,000 -
Otherlong-termpayables 30,831 -
Total currentliabilities 30,995,381 31,110,617
including: currentpayables
debt 27,995,381 31,110,617
Overdue current debts - -
Debtsto suppliers andcontractors 27,183,988 29,469,107
Arrears toseparatedivisions - -
Debts to subsidiaries and affiliates 217,646 408,189
Deferred revenue - -
Deferred taxes and liabilities, payments - -
Advances received 22,784 11,388
PROFIT & LOSS ACCOUNT as at 30/09/2010 (9
months period) and 31/12/2009 (12 months period)
31/12/2009 30/09/2010
(In thousand SUM)
Net proceedsfromthe sale
of products(goods, works
andservices) 65,353,653 87,646,624
Cost ofgoods sold
(goods, works and
services)(62,862,417)
(83,490,200)
Grossprofit(loss) from
saleof goods (works,
services) 2,491,236 4,156,424
Expenses for the period (4,347,671) (6,763,242)
Distribution costs (1,624,870) (3,003,415)
Administrativeexpenses (553,487) (1,136,967)
Other operatingexpenses (2,169,314) (2,622,860)
Otheroperating income 11,912,965 14,890,474
Income (loss) from operations 10,056,530 12,283,656
Incomefrom
financing activities,
total, including: 177,246 668,441
Income fromdividends - 132,194
Interest income - -
Income from long-term lease - -
Incomefromforeign
currencyexchange 177,246 536,247
Otherincomefrom
financingactivities - -
Expensesfromfinancing
activities, total,
including: (2,541,767) (1,339,166)
Interest expenses (834,816) (73,251)
Interest expenseson
financialleasing - -
Losses from currency
exchange differences(1,706,951) (1,265,915)
Other expenses from financial
activities - -
Profit(loss) ongeneral
businessactivities 7,692,009 11,612,931
Profit(loss) before
taxes on income(profit) 7,692,009 11,612,931
Taxon income(profit) 25,526 9,090
Othertaxesandleviesonprofits
(1,885,833)
(2,558,885)
Net income (loss) for
the reporting period 5,806,176 9,054,046
Historical profit and loss account:
Sales
Turnover
: SUM 400,000,000 -
1998 - exact
: SUM 577,307,000 -
1999 - exact
: SUM 2,118,100,000 - 2000 - exact
: SUM 3,400,000,000 - 2001 - exact
: SUM 5,500,000,000 - 2002 - exact
: SUM 11,477,000,000 - 2003 - exact
: SUM 12,930,000,000 - 2004 - exact
: SUM 17,351,800,000 - 2005 - exact
: SUM 20,447,660,000 - 2006 - exact
: SUM 29,647,000,000 - 2007 - exact
: SUM 55,396,210,000 - 2008 - exact
: SUM 96,906,105,000 - 2009 - exact
: SUM 117,545,538,000 - 2010 - exact
Net Profit (before tax) :
SUM 20,000,000 -
1998 - exact
: SUM 36,858,200
- 1999 - exact
: SUM 136,015,000 -
2000 - exact
: SUM
3,800,000 - 2001 - exact *
: SUM 500,000,000 -
2002 - exact
: SUM 1,100,000,000 - 2003 - exact
: SUM 389,000,000 -
2004 - exact
: SUM 610,707,000 - 2005 - exact
: SUM 1,436,930,000 - 2006 - exact
: SUM 3,336,000,000 - 2007 - exact
: SUM 6,319,178,000 - 2008 - exact
: SUM 14,491,025,000 - 2009 - exact
: SUM 16,644,623,000 - 2010 - exact
Net Profit (after tax) :
SUM 59,175,000 -
2005 - exact
: SUM 617,793,000 -
2006 - exact
: SUM 2,446,000,000 - 2007 - exact
: SUM 12,220,631,000 - 2010 - exact
* Sharp decrease
in profit in 2001 was due to unfavourable exchange
rate and low mark-up.
Financial year ends 31 December.
The
following financial information applies to subject’s subsidiary company, Bukhara Dori-DarmonDP :
Sales
Turnover : SUM 12,000,000,000 – 2009
– exact
: SUM 13,500,000,000 – 2010
– exact
: SUM 15,000,000,000 – 2011
– projected
Net
Profit : SUM 450,000,000 – 2009 – exact
: SUM 500,000,000 – 2010 – exact
Financial
year ends 31 December.
The
following financial information applies to subject’s subsidiary company, Fergana DoriDarmonOAO :
Sales
Turnover : SUM 850,000,000 - 2001 - exact
: SUM 1,500,000,000 - 2002 - exact
: SUM 2,000,000,000 - 2003 - exact
: SUM 2,600,000,000 - 2005 - exact
: SUM 2,504,405,000 - 2006 - exact
: SUM 3,540,792,000 - 2007 – exact
: SUM 4,774,702,300 – 2008 – exact
: SUM 8,234,106,600 – 2009 – exact **
: SUM 11,799,578,000 – 2010
– exact
: SUM 7,250,000,000 – 2011 – exact ***
: SUM 14,000,000,000 – 2011
– projected
Net
Profit : SUM 21,000,000 - 2001 - exact
: SUM 41,000,000 - 2002 - exact
: SUM 40,000,000 - 2003 - exact
: SUM
26,000,000 - 2005 - exact *
: SUM 36,947,900 - 2006 - exact
: SUM 50,580,900 - 2007 – exact
: SUM 124,439,000 – 2008 – exact
: SUM 719,675,000 – 2009 – exact **
: SUM 560,953,000 – 2010 – exact
* In
2005 Profit decreased due to extra expenses in relation to
payment
of bank loan.
** A
significant increase in sales turnover and net profit in 2009 was attributed to
favourable market conditions and expansion of the business.
*** 6
months results (January - June).
Financial
year ends 31 December.
The
following financial information applies to subject’s subsidiary company, SyrdaryaDori-DarmonDP :
Sales
Turnover : SUM 1,750,000,000 – 2008
– exact
: SUM 3,511,000,000 – 2009
– exact
: SUM 6,235,351,000 – 2010
– exact *
: SUM 7,000,000,000 – 2011
– projected
Net
Profit : SUM 86,200,000 – 2009 – exact
: SUM 278,000,000 – 2010 – exact *
Financial
year ends 31 December.
LEGAL
STATUS AND HISTORY
Date Started :11
April 1994
History :
On 1 August
1922, at the Public Healthcare commissariat of
the Turkistan Independent Soviet Socialistic Republic the Pharmaceutical
Department was instituted.
In 27 October 1924, the Uzbek Soviet Socialistic Republic was organized,
and in February, 1925 at the Public
Healthcare commissariat the Pharmaceutical Department was opened. 34 self-financing drugstores, the
central pharmacy warehouse, the analytical control laboratory and galenic
laboratory were in its authority.
Because of enlargement of the drugstore net in November, 1938, the Pharmaceutical Department of
Uzbekistan was reorganized to the Main Pharmaceutical Department (MPD).
For the purpose of approaching the healthcare and pharmacy services to village people, from 1938 in
countryside medicinal departments of Uzbekistan the pharmacy subdivisions were
being organized and to 1940 the quantity of drugstores in the Republic
increased up to 172.
At the end of 1940 in MPD system 172 drugstores, 398 pharmacy subdivisions, 20
pharmacy shops, 76 pharmacy kiosks, 5 warehouses, 6 analytical control
laboratories and 1 galenic laboratory operated.
During war years to the pharmacy system of Uzbekistan face a lot of challenges
and the Republic pharmacists solved them
successfully. MPD of the Republic in first priority delivered the medicinal
preparations to evacuation clinics, therapeutic institutions for children and
medical sanitary units of the industrial plants of the defense direction.
After war the following intensive development of the drugstore net continued, the work of the
pharmaceutical
institutions, supporting of workers of industrial plants and agricultural sector in medicines was
improved. Only
during the period 1959-1975 888 new drugstores were opened in the Republic,
including 652 drugstores located in the countryside.
The new drugstores were built mainly according to the standard projects. During the period from
1971 to 1977 more than 140 typical drugstores were built and 130 drugstores moved to the new modern buildings.
In June 1978 in Tashkent the City Central training- production drugstore was
opened.
At the beginning of 1981, 1,500 drugstores (including 1,016 drugstores in countryside), 3434 pharmacy
subdivisions (from them 217 of the first
grade), 25 pharmacy shops, 14 pharmacy warehouses and 14 analytical control
laboratories were in the Main Pharmaceutical Department system of the Ministry
of Health.
One of the crucial factors for the following development of
the pharmacy net and improving the quality of the support for the people was
the sufficient personnel.
In 1958, in the Republican pharmacy net, 1,490 professionals worked in pharmacy
(including 553 pharmacists
with high
pharmaceutical education). In 1981, 3,150 qualified pharmacists (specialists of
high pharmaceutical
education)
and 2,970 pharmacists (specialists of secondary level special education) worked
in the pharmacy field.
In 1984 the net of the Central Regional Drugstores (CRD) was organized, including 9 drugstores in
Tashkent.
In 1987 in the Republic 1995 self-financing drugstores, including 1333 in countryside, and 6477
pharmaceutical subsidiaries were in
operation. In therapeutic and prophylactic
institutions were 445 in-hospital pharmacies.
In 1988 the Main Pharmaceutical Department were reorganized to «Farmacia» Republican industrial
association.
On the base of Resolution No.132 by the Cabinet of Ministers
of the Republic of Uzbekistan «On the destatization and privatization of the
pharmacy institutions of the system of the Ministry of Health of the Republic
of Uzbekistan» dated from 11 March 1994, «Farmacia» Republican industrial
association at the Ministry of Health of the Republic of Uzbekistan from the 9-th
of April, 1994 was reorganized to the «Dori-Darmon» State joint-stock
association.
On the base of ResolutionNo.131 by the
Cabinet of Ministers of the Republic of Uzbekistan dated from 20 May
2005, the
«Dori-Darmon» State joint-stock association was reorganized to «Dori-Darmon»
joint-stock company having the state share of 36.1%. «Dori-Darmon» joint-stock
company is a legal successor of the Republic Pharmaceutical Department.
C.R. No. : 27, as of 1 June 1994, Ministry of Justice
Tax No. : INN 201389395
Statistics Code : OKPO 02027227
Activity
Code :OKONKh 71212
Authorised Capital : SUM 16,057,600,000 (increased from SUM
8,028,800,000
in October 2010)
Paid up Capital : SUM 16,057,600,000 (increased from SUM
8,028,800,000
in October 2010)
AktsyonernayaKompaniya (joint stock company) with the following
shareholders :
No
of Shares Percentage
1. GoskomimushchestvoRespubliki Uzbekistan
7245730 36.1%
Government regulated body
2. Chester Trading & Investments
LLC 7005128
34.9%
285 Liberty, Oregon
Salem
USA
3.AvazAshrapovichLipatov 16722
0.083%
4.UmidaSaidovnaSalihbaeva
7334 0.037%
5.MirmasudSalihovichFajziev
16722
0.083%
6.IlezZhabarovichRazakov
16722 0.083%
7.OkilNigmanovichHodzhimetov
16722 0.083%
8.SaidvaliSaidnabievichNasretdinov
16111 0.08%
9.Tatyana
JuryevnaNikulina
15500 0.077%
10.Umida
BobokolanovnaRuzieva 15500
0.077%
11. 2,500 minority
shareholders 28.397%
Affiliated companies of Dori-DarmonAK :
Subsidiaries
1. Dori-Darmon Invest OOO
ploshchadAkhunbabaeva 21
Tashkent 100021
Tel: (998 71) 120 3824 / 120 4848
Fax: (998 71) 120 3824
Est. : 8 June 2004
2. Dori-DarmonGarant DP
ploshchadAkhunbabaeva 21
Tashkent 100021
Tel: (998 71) 144 0097 / 120 3836
Fax: (998 71) 144 8368 / 120 3835
3. Dori-Darmon HCP DP
ulitsaRashidova 40 a
Tashkent 100029
Tel: (998 71) 256 3600 / 256 3700
Fax: (998 71) 256 3700
Est. : 3 December 2007
4. Uzb.Dori-Taminoti DP
ulitsaMirpulatova 1a
Tashkent 100029
Tel: (998 71) 148 1556 / 148 1038 / 248 2836 / 148 1554
Fax: (998 71) 248 2223 / 148 1556
Tax No. : INN 201389395
5. KarikalpakDori-Darmon DP
Nukus
6.SurkhanDori-Darmon DP
ulitsaIkramova 119
Termez 132000
Tel: (998 7622) 37982
7. SyrdaryaDori-Darmon DP
Gulistan 107000
Tel: (998 672) 272 240
8. KhorezmDori-Darmon DP
Dzhizakh
9. Bukhara Dori-Darmon DP
ulitsaGagarina 40
Bukhara 705000
Tel: (998 65) 225 2181 / 225 3615
Fax: (998 65) 225 2307 / 225 7506
Est. : 3 May 1995
Tax No. : INN 200851700
10.HPDori-Darmon
DP
Tashkent
Associates
1. Andizhan Dori-Darmon AO
ulitsaIstiklol 1
Andizhan 110012
Tel: (998 374) 224 2550
2. KashkadaryaDori-Darmon AO
ulitsa Uzbekistan ovozi 25
Karshi 130000
Tel: (998 7522) 37940
3. Namangan Dori-Darmon AO
ulitsaNosira 12
Namangan 116000
Tel : (998 369) 226 3731
4. NavoiDori-Darmon AO
ulitsaNavoi 65
Navoi 106800
Tel: (998 79) 224 4700
5. Samarkand Dori-Darmon AO
prospektSuperfosfatniy
Samarkand 103901
Tel: (998 662) 341 836 / 343 294
Fax: (998 662) 251 779 / 251 780
6. Dori-DarmonTashkentskoyOblasti AO
ulitsa Yusuf KhosKhozhib
Yakkasarayskiy rayon
Tashkent 100031
Tel: (998 71) 256 4159 / 256 5449
Fax: (998 71) 256 3743
7. TashkentskiyGorodskoyDori-Darmon AO
ploshchadAkhunbabaeva 21
Tashkent 100021
Tel: (998 71) 248 7582
Fax: (998 71) 248 7684
ACTIVITIES
The Company
is involved in the following activities :
Importers, wholesalers and retailers of pharmaceuticals.
Subject also engages in production of pharmaceutical products.
Subject provides management services and coordinates operations of
its subsidiaries and associated companies trading in pharmaceutical
products.
Subject mainly supplies to state owned hospitals.
NACE Code
:2110 / 4646
Imports from Germany, Austria, UK, France, Netherlands, Hungary,
Slovenia, Finland, Poland, Switzerland, Latvia, Belgium, Turkey,
Georgia, Russia, Ukraine, Belarus and India.
Subject does not export, all sales are domestic.
FACILITIES
The Company has the following facilities :
Owned premises comprising a pharmacy, storage facilities, production
unit and offices located at the heading address as well as a
warehouse located at Mirpulatovkuchesi 1A, Tashkent 700069. Subject
also has 18 warehouses, 15 analytical control laboratories, 656
pharmacy institutions, including 410 located in countryside.
Until October 2003, subject's administrative offices were located at
Mirpulatovkuchesi 1A, Tashkent 700069 (formerly known as Mirza
Mavlyanovkuch. 1A, 700069 Tashkent).
BRANCH OFFICES
1.ulitsa Al Fargoniy 50
Fergana
Tel: (998 73) 249 028
Fax: (998 73) 248 336
2. ulitsaIkramova 119
Termez
Surkhandaryinskaya Oblast
Tel: (998 732002) 35308 / 35307
Fax: (998 732002) 37982
3. ulitsNosyra 12
Namangan
Tel: (998 69) 64011
Fax: (998 69) 62478
4. ulitsaNavoi 65
Navoi
Tel: (998 79) 45451
Fax: (998 79) 44700
6. ulitsaUzbekistonOvozi 25
Karshi
Kashkadaryinskay oblast
Tel: (998 75) 39975 / 39980
Fax: (99875) 32585
7. Pharmacy No. 9
Massiv 8A, dom 18, kv. 37
Tashkent
Tel: (998 71) 215 1752
8. ulitsaNosira 122, kv. 3
Tashkent
Tel: (998 712) 509 176
SPECIAL NOTE
You enquired on :J
S C DoriDarmon. Please note that the correct name is as per heading.
Interviewed :MuatarRakhimzhanova
(Deputy Chief Accountant)
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.52.70 |
|
UK Pound |
1 |
Rs.82.44 |
|
Euro |
1 |
Rs.71.08 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.